247 related articles for article (PubMed ID: 35533704)
1. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study.
Deutschbein T; Reimondo G; Di Dalmazi G; Bancos I; Patrova J; Vassiliadi DA; Nekić AB; Debono M; Lardo P; Ceccato F; Petramala L; Prete A; Chiodini I; Ivović M; Pazaitou-Panayiotou K; Alexandraki KI; Hanzu FA; Loli P; Yener S; Langton K; Spyroglou A; Kocjan T; Zacharieva S; Valdés N; Ambroziak U; Suzuki M; Detomas M; Puglisi S; Tucci L; Delivanis DA; Margaritopoulos D; Dusek T; Maggio R; Scaroni C; Concistrè A; Ronchi CL; Altieri B; Mosconi C; Diamantopoulos A; Iñiguez-Ariza NM; Vicennati V; Pia A; Kroiss M; Kaltsas G; Chrisoulidou A; Marina LV; Morelli V; Arlt W; Letizia C; Boscaro M; Stigliano A; Kastelan D; Tsagarakis S; Athimulam S; Pagotto U; Maeder U; Falhammar H; Newell-Price J; Terzolo M; Fassnacht M
Lancet Diabetes Endocrinol; 2022 Jul; 10(7):499-508. PubMed ID: 35533704
[TBL] [Abstract][Full Text] [Related]
2. Clinical course of patients with adrenal incidentalomas and cortisol autonomy: a German retrospective single center cohort study.
Remde H; Kranz S; Morell SM; Altieri B; Kroiss M; Detomas M; Fassnacht M; Deutschbein T
Front Endocrinol (Lausanne); 2023; 14():1123132. PubMed ID: 37223045
[TBL] [Abstract][Full Text] [Related]
3. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.
Patrova J; Kjellman M; Wahrenberg H; Falhammar H
Endocrine; 2017 Nov; 58(2):267-275. PubMed ID: 28887710
[TBL] [Abstract][Full Text] [Related]
4. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas : A Cohort Study.
Kjellbom A; Lindgren O; Puvaneswaralingam S; Löndahl M; Olsen H
Ann Intern Med; 2021 Aug; 174(8):1041-1049. PubMed ID: 34029490
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
Araujo-Castro M; Parra Ramírez P; Robles Lázaro C; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2021 Dec; 20(4):735-744. PubMed ID: 34273083
[TBL] [Abstract][Full Text] [Related]
6. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
J Endocrinol Invest; 2021 Nov; 44(11):2349-2357. PubMed ID: 33683661
[TBL] [Abstract][Full Text] [Related]
7. Mortality Not Increased in Patients With Nonfunctional Adrenal Adenomas: A Matched Cohort Study.
Kjellbom A; Lindgren O; Danielsson M; Olsen H; Löndahl M
J Clin Endocrinol Metab; 2023 Jul; 108(8):e536-e541. PubMed ID: 36800277
[TBL] [Abstract][Full Text] [Related]
8. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; Cuesta Hernández M; Sampedro Núñez MA; Marazuela M
Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
[TBL] [Abstract][Full Text] [Related]
9. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis.
Pelsma ICM; Fassnacht M; Tsagarakis S; Terzolo M; Tabarin A; Sahdev A; Newell-Price J; Marina L; Lorenz K; Bancos I; Arlt W; Dekkers OM
Eur J Endocrinol; 2023 Oct; 189(4):S88-S101. PubMed ID: 37801655
[TBL] [Abstract][Full Text] [Related]
10. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Tsagarakis S; Terzolo M; Tabarin A; Sahdev A; Newell-Price J; Pelsma I; Marina L; Lorenz K; Bancos I; Arlt W; Dekkers OM
Eur J Endocrinol; 2023 Jul; 189(1):G1-G42. PubMed ID: 37318239
[TBL] [Abstract][Full Text] [Related]
11. Subclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo M; Osella G; Alì A; Borretta G; Cesario F; Paccotti P; Angeli A
Clin Endocrinol (Oxf); 1998 Jan; 48(1):89-97. PubMed ID: 9509073
[TBL] [Abstract][Full Text] [Related]
12. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Arlt W; Bancos I; Dralle H; Newell-Price J; Sahdev A; Tabarin A; Terzolo M; Tsagarakis S; Dekkers OM
Eur J Endocrinol; 2016 Aug; 175(2):G1-G34. PubMed ID: 27390021
[TBL] [Abstract][Full Text] [Related]
13. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.
Rossi R; Tauchmanova L; Luciano A; Di Martino M; Battista C; Del Viscovo L; Nuzzo V; Lombardi G
J Clin Endocrinol Metab; 2000 Apr; 85(4):1440-8. PubMed ID: 10770179
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of new recommendations for adrenal incidentalomas in the evaluation of excessive cortisol secretion and follow-up.
Ruiz A; Michalopoulou T; Megia A; Näf S; Simón-Muela I; Solano E; Martínez L; Vendrell J
Eur J Clin Invest; 2019 Feb; 49(2):e13048. PubMed ID: 30412278
[TBL] [Abstract][Full Text] [Related]
15. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.
Tsagarakis S; Kokkoris P; Roboti C; Malagari C; Kaskarelis J; Vlassopoulou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 May; 48(5):627-33. PubMed ID: 9666875
[TBL] [Abstract][Full Text] [Related]
16. Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up.
Yener S; Baris M; Peker A; Demir O; Ozgen B; Secil M
Clin Endocrinol (Oxf); 2017 Nov; 87(5):425-432. PubMed ID: 28656620
[TBL] [Abstract][Full Text] [Related]
17. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
Araujo-Castro M; Hanzu FA; Pascual-Corrales E; García Cano AM; Marchan M; Escobar-Morreale HF; Valderrabano P; Casals G
Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
[TBL] [Abstract][Full Text] [Related]
18. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
[TBL] [Abstract][Full Text] [Related]
19. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
Araujo-Castro M; Parra Ramírez P; Martín Rojas-Marcos P; García Centeno R; Gracia Gimeno P; Tomé Fernández-Ladreda M; Sampedro Núñez MA; Higueruela C; Robles Lázaro C
Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.
Di Dalmazi G; Vicennati V; Garelli S; Casadio E; Rinaldi E; Giampalma E; Mosconi C; Golfieri R; Paccapelo A; Pagotto U; Pasquali R
Lancet Diabetes Endocrinol; 2014 May; 2(5):396-405. PubMed ID: 24795253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
